The University of Sheffield and Parkinson’s UK have launched a new £1million virtual biotech company in the next stage[1] of a pioneering research programme to create new drugs for Parkinson’s.

In a partnership that is the first of its kind, Keapstone Therapeutics will combine world-leading research from the University with funding and expertise from the charity to he...

Parkinson's UK and MedGenesis Therapeutix Inc. announced today that the Phase 2 clinical trial evaluating the safety and efficacy of glial cell line-derived neurotrophic factor (GDNF) in Parkinson's disease, delivered via intermittent bilateral intraputamenal infusions using convection enhanced delivery (CED) and conducted at Southmead Hospital by the North Bristol N...